May 18, 2026
Schedule 13D, amended
WEI-WU HE, Ph.D.: 58.8%, 23,985,535 shares
Mar 23, 2026
Schedule 13D, amended
WEI-WU HE, Ph.D.: 53%, 18,985,535 shares
Dec 31, 2025
Schedule 13G, amended
Venrock Healthcare Capital Partners III, L.P.: 9.2%, 1,987,259 shares
Dec 31, 2025
Schedule 13G, amended
Foresite Capital Fund VI LP: 0%, 0 shares
Feb 9, 2026
Schedule 13D, amended
WEI-WU HE, Ph.D.: 45.4%, 13,965,535 shares
Jan 27, 2026
Schedule 13D, amended
WEI-WU HE, Ph.D.: 34.8%, 8,965,535 shares
Sep 30, 2025
Schedule 13D, amended
Zhou Quan: 4.8%, 992,638 shares
Sep 30, 2025
Schedule 13D, amended
SPARKLE BYTE LTD: 5%, 1,019,852 shares
Jan 9, 2026
Schedule 13D, amended
WEI-WU HE, Ph.D.: 19.1%, 3,965,535 shares
Dec 18, 2025
Schedule 13D, amended
WEI-WU HE, Ph.D.: 19.1%, 3,965,535 shares
Dec 16, 2025
Schedule 13D, amended
James Huang: 22.5%, 4,651,527 shares
Sep 30, 2025
Schedule 13G
Chen Zhenfeng: 11%, 2,255,636 shares
Sep 30, 2025
Schedule 13G, amended
Foresite Capital Fund VI LP: 6.3%, 979,956 shares
Sep 26, 2025
Schedule 13D
James Huang: 19.9%, 3,661,571 shares
Schedule 13D is filed within 5 business days of crossing 5 percent by an investor who may seek to influence the company. Schedule 13G is filed by a passive holder, and a large institution has up to 45 days after the quarter end.